The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > AutoImmune Inc.

AutoImmune Inc.
Nasdaq: AIMM
Change
symbol:
     
 PROFILE
Biopharmaceutical company AutoImmune develops orally administered drugs for the treatment of immune system and inflammatory diseases. Disappointing test results prompted AutoImmune to stop development of Colloral, its most advanced product, as a possible treatment for rheumatoid arthritis; the firm is seeking FDA approval to sell the drug as a nutraceutical. Other drugs in various stages of development target such disorders as diabetes and multiple sclerosis. The firm has agreements with such drug makers as Teva Pharmaceutical and Eli Lilly to perform research, conduct drug trials, and license technologies.

 COMPETITION
Alteon Inc. (ALT)
Biogen, Inc. (BGEN)
Serono S.A. (SRA)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 4.00
1-Yr. Sales Growth: 3,900.0%

 KEY PEOPLE
• Robert C. Bishop
    CEO
• Heather A. Ellerkamp
    CFO

 CONTACT INFO
1199 Madia St.
Pasadena, CA 91103
US
Phone: 626-792-1235
Fax: -
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001